Maxim Group Analysts Give Athersys, Inc. (ATHX) a $12.00 Price Target
Athersys, Inc. (NASDAQ:ATHX) has been given a $12.00 price target by research analysts at Maxim Group in a report issued on Thursday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s target price suggests a potential upside of 390.80% from the stock’s current price.
Other research analysts have also issued research reports about the stock. Zacks Investment Research raised shares of Athersys from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a research report on Thursday, September 7th. ValuEngine lowered shares of Athersys from a “hold” rating to a “sell” rating in a research report on Monday. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $7.17.
Shares of Athersys (NASDAQ ATHX) traded up 14.49% during mid-day trading on Thursday, reaching $2.45. The company had a trading volume of 2,469,747 shares. The company’s market capitalization is $279.08 million. The company’s 50-day moving average price is $2.04 and its 200-day moving average price is $1.64. Athersys has a 52-week low of $1.02 and a 52-week high of $2.63.
Athersys (NASDAQ:ATHX) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.06). The business had revenue of $0.67 million during the quarter, compared to analyst estimates of $0.96 million. Athersys had a negative net margin of 729.07% and a negative return on equity of 121.47%. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.08) earnings per share. On average, analysts forecast that Athersys will post ($0.24) earnings per share for the current fiscal year.
In related news, insider William Lehmann, Jr. sold 15,000 shares of the stock in a transaction dated Tuesday, September 19th. The shares were sold at an average price of $2.38, for a total value of $35,700.00. Following the completion of the transaction, the insider now owns 527,380 shares of the company’s stock, valued at $1,255,164.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 9.40% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in Athersys by 19.5% in the first quarter. Vanguard Group Inc. now owns 3,899,200 shares of the biopharmaceutical company’s stock worth $6,668,000 after purchasing an additional 637,322 shares in the last quarter. Wells Fargo & Company MN raised its position in Athersys by 4.8% in the first quarter. Wells Fargo & Company MN now owns 61,176 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 2,800 shares in the last quarter. Teachers Advisors LLC raised its position in Athersys by 21.9% in the fourth quarter. Teachers Advisors LLC now owns 156,880 shares of the biopharmaceutical company’s stock worth $240,000 after purchasing an additional 28,178 shares in the last quarter. Geode Capital Management LLC raised its position in Athersys by 35.2% in the first quarter. Geode Capital Management LLC now owns 756,004 shares of the biopharmaceutical company’s stock worth $1,292,000 after purchasing an additional 196,981 shares in the last quarter. Finally, FNY Partners Fund LP acquired a new position in Athersys in the first quarter worth about $206,000. 19.08% of the stock is owned by hedge funds and other institutional investors.
Athersys Company Profile
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.